Study guide

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose

NBRC RRT-NPS Neonatal/Pediatric Specialist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neonatal and Pediatric Patient Assessment

1.1 Maternal, Obstetric & Perinatal History 1.2 Fetal Surveillance & Antepartum Diagnostics 1.3 Gestational Age & Baseline Neonatal Examination 1.4 Apgar, Respiratory Distress & Thoracic Assessment 1.5 Pediatric Assessment Triangle & Vital Signs 1.6 Neurologic Assessment, Respiratory Failure & Triage

2 Chapter 2: Diagnostic Evaluation & Gas Exchange Monitoring

2.1 Pulse Oximetry, Pre/Postductal & Transcutaneous Monitoring 2.2 Capnography, Waveforms & Dead-Space Evaluation 2.3 Arterial & Capillary Blood-Gas Sampling 2.4 Umbilical Lines, Acid-Base & Laboratory Evaluation 2.5 Chest Imaging & Airway Radiography 2.6 Pulmonary Function, Bronchoscopy & Specimen Diagnostics

3 Chapter 3: Airway Management & Secretion Clearance

3.1 Pediatric Airway Anatomy & ETT Sizing 3.2 Cuffed Airways, Intubation & Difficult-Airway Management 3.3 Tracheostomy Devices & Routine Care 3.4 Tracheostomy Emergencies, Speaking & Decannulation 3.5 Airway Suctioning Technique & Safety 3.6 Airway Clearance, Home Care & Discharge Planning

4 Chapter 4: Pharmacology & Medical Gas Therapy

4.1 Aerosol Physics & Delivery Devices 4.2 Respiratory & Systemic Pharmacology 4.3 Oxygen Interfaces & Delivery Systems 4.4 Oxygen Blenders, Targets & Toxicity 4.5 HFNC Physiology, Sizing & Flow 4.6 HFNC Indications, Monitoring & Escalation

5 Chapter 5: Shared Neonatal & Pediatric Pulmonary Disorders

5.1 Neonatal RDS Pathophysiology & Management 5.2 TTN, Pneumonia & the Neonatal Differential 5.3 Meconium Aspiration & PPHN 5.4 BPD, Apnea & Chronic Neonatal Lung Disease 5.5 Bronchiolitis, Croup & Epiglottitis 5.6 Asthma, Cystic Fibrosis & Foreign-Body Aspiration

6 Chapter 6: Resuscitation, Emergency Protocols & Patient Safety

6.1 NRP Cord Management, Initial Steps & Ventilation 6.2 NRP Corrective Steps, Compressions & Medications 6.3 PALS Assessment, CPR & Cardiac Arrest 6.4 PALS Dysrhythmia & Shock Management 6.5 Neonatal & Pediatric Transport 6.6 Patient Safety, Teamwork & Family-Centered Care

7 Chapter 7: Noninvasive & Conventional Mechanical Ventilation

7.1 Bubble CPAP & Neonatal NIV 7.2 Pediatric NIV, Interfaces & Failure Recognition 7.3 Conventional Ventilation Physics & Modes 7.4 Initial Settings & ABG-Guided Titration 7.5 Ventilator Scalars & Loops 7.6 Ventilator Dyssynchrony & Troubleshooting 7.7 Weaning Readiness & Spontaneous Breathing Trials 7.8 Extubation & Post-Extubation Airway Risk

8 Chapter 8: High-Frequency Ventilation & Advanced Modes

8.1 HFOV Mechanics & Gas Transport 8.2 HFOV Controls & Clinical Management 8.3 HFJV Circuit & Controls 8.4 HFJV Servo Pressure & Clinical Indications 8.5 NAVA, Edi & Proportional Support 8.6 APRV in Pediatric Respiratory Failure

9 Chapter 9: Specialty Inhaled Gases & Exogenous Surfactant Therapy

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose 9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning 9.3 Heliox Physics & Delivery 9.4 Volatile Anesthetic & Subambient Gas Therapy 9.5 Surfactant Biology, Products & Dosing 9.6 Surfactant Administration & Response

10 Chapter 10: Pediatric ARDS & Parenchymal Critical Illness

10.1 PALICC-2 Diagnosis & Severity 10.2 PALICC-2 NIV & Possible PARDS 10.3 PARDS Lung-Protective Ventilation 10.4 PARDS Refractory Hypoxemia & Adjuncts 10.5 PIE & Pneumothorax Recognition 10.6 Thoracic Decompression & Chest Drains

11 Chapter 11: Congenital Heart Disease & Hemodynamic Management

11.1 Left-to-Right Shunts & Qp/Qs Physiology 11.2 Acyanotic Lesions & Respiratory Management 11.3 Cyanotic Lesions & the Five Ts 11.4 Ductal Dependence, PGE1 & the Hyperoxia Test 11.5 Single-Ventricle Physiology & Staged Palliation 11.6 Gas Balancing, Hemodynamics & NIRS

12 Chapter 12: Advanced Critical Care: ECMO, Neurotrauma & Palliative Care

12.1 ECMO Candidacy & Modality 12.2 ECMO Circuit, Lung Rest & Anticoagulation 12.3 Neurotrauma, ICP & Ventilation 12.4 Neonatal Therapeutic Hypothermia & Respiratory Care 12.5 Death by Neurologic Criteria: Examination & Apnea Testing 12.6 DNC Timing, Ancillary Testing, Palliation & Donation

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose

Key Takeaways Explain This Topic AI

Inhaled nitric oxide activates soluble guanylyl cyclase and raises cGMP in ventilated lung regions. Rapid hemoglobin scavenging makes its vascular effect largely pulmonary-selective, although systemic hypotension and worsening heart failure can occur.

The FDA-labeled neonatal indication is hypoxic respiratory failure with clinical or echocardiographic pulmonary hypertension in term and near-term infants over 34 weeks gestation, together with ventilatory support and other therapy; the label does not require one fixed OI cutoff.

For term or near-term PPHN, 20 ppm is the usual starting dose. Higher doses generally add toxicity without proven outcome benefit; evaluate lung recruitment, anatomy, ventricular function, delivery accuracy, and alternative escalation when response is inadequate.

Last updated: September 2026

9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose

Inhaled nitric oxide (iNO) is an uncharged, lipophilic gas that serves as an endogenous cell-signaling molecule and a revolutionary targeted pharmacotherapy in neonatal and pediatric critical care. In the transitioning newborn, failure of pulmonary vascular resistance (PVR) to fall normally after birth leads to Persistent Pulmonary Hypertension of the Newborn (PPHN) . Elevated pulmonary arterial pressure exceeding systemic arterial pressure drives unoxygenated venous blood across fetal right-to-left shunts (the patent ductus arteriosus and patent foramen ovale), resulting in life-threatening hypoxemia refractory to conventional mechanical ventilation. Inhaled nitric oxide reverses this pathophysiological cycle by providing potent, selective pulmonary vasodilation.

Molecular Mechanism of Action & Selective Pulmonary Vasodilation

Understanding the cellular pathway of nitric oxide is fundamental to mastering its clinical pharmacology and avoiding systemic adverse events. [Inhaled Nitric Oxide (iNO) in Alveolus]

  • │
  • │ Rapid Alveolar-Capillary Diffusion
  • ▼
  • [Pulmonary Vascular Smooth Muscle Cell]
  • │
  • ▼
  • Activates Soluble Guanylyl Cyclase (sGC)
  • │
  • ▼
  • GTP ─────────► cGMP
  • │
  • ▼
  • Stimulates Protein Kinase G (PKG)
  • │
  • ┌──────────────────────┴──────────────────────┐
  • ▼ ▼
  • Dephosphorylates Myosin Sequester Intracellular Ca2+
  • Light Chains & Block Voltage-Gated Influx
  • │ │
  • └──────────────────────┬──────────────────────┘
  • ▼
  • PULMONARY VASODILATION
  • │
  • │ Transits into Capillary Lumen
  • ▼
  • [Erythrocyte in Blood]
  • │
  • Binds Hemoglobin with Ultra-High Affinity
  • (Forms Nitrosyl-Hb ──► Rapidly Oxidized to MetHb)
  • │
  • ▼
  • PREDOMINANT PULMONARY EFFECT / MONITOR SYSTEMIC PRESSURE
  • 1. Cellular Signal Transduction

Diffusion: Following inhalation, gaseous NO diffuses rapidly across the alveolar epithelial membrane, the interstitial space, and the capillary endothelial wall directly into adjacent vascular smooth muscle cells.

Enzyme Activation: NO binds with high affinity to the heme moiety of soluble guanylyl cyclase (sGC) , inducing a conformational change that accelerates the catalytic conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) .

Calcium Extrusion & Muscle Relaxation: Elevated intracellular cGMP activates cGMP-dependent protein kinase G (PKG). PKG phosphorylates specific target proteins, resulting in:

Phosphorylation and activation of sarcoplasmic reticulum calcium-ATPase (SERCA), pumping free Ca 2 + \text{Ca}^{2+} Ca 2 + into the sarcoplasmic reticulum.

Inhibition of voltage-dependent L-type calcium channels, halting extracellular calcium influx.

Dephosphorylation of myosin light chains via activation of myosin light chain phosphatase.

Result: Intracellular calcium concentrations plunge, producing rapid vascular smooth muscle relaxation and arteriolar dilation.

Metabolism: Cellular cGMP is subsequently degraded into inactive 5'-GMP by the enzyme phosphodiesterase type 5 (PDE-5) . (This enzyme is the pharmacological target of sildenafil, which prevents cGMP breakdown and sustains vasodilation).

2. The Twin Hallmarks of Selectivity

What distinguishes iNO from systemic vasodilators (e.g., nitroprusside, hydralazine, prostacyclin infusions) is its double selectivity:

Ventilation-Perfusion (V/Q) Selectivity (Intrapulmonary Targeting):

Because iNO is delivered via the gas phase, it enters only well-ventilated lung units .

Pulmonary arterioles adjacent to well-ventilated alveoli dilate, redistributing pulmonary blood flow away from non-ventilated, atelectatic, or consolidated regions toward ventilated alveoli.

This microvascular redistribution dramatically improves V / Q V/Q V / Q matching, decreases intrapulmonary right-to-left shunt, and improves arterial oxygenation without causing generalized hyperperfusion of collapsed lung segments.

Relative Pulmonary Circulation Selectivity:

As soon as iNO transits across the vascular wall into the capillary lumen, it encounters circulating red blood cells.

Free NO binds instantly to the iron in hemoglobin with an affinity approximately 200,000 times greater than that of oxygen ( K d ≈ 10 − 12 M K_d \approx 10^{-12}\text{ M} K d ​ ≈ 1 0 − 12 M ).

This reaction rapidly forms nitrosyl-hemoglobin (Hb-NO), which is swiftly oxidized in the presence of oxygen to methemoglobin ( MetHb \text{MetHb} MetHb ) and inactive nitrate/nitrite compounds.

The biological intravascular half-life of free iNO in the blood is < 0.1 seconds < 0.1\text{ seconds} < 0.1 seconds (milliseconds). Consequently, hemoglobin scavenging limits systemic vasodilation and makes the effect predominantly pulmonary. It is not absolute: hypotension is a reported adverse reaction, and increased pulmonary venous return can worsen pulmonary edema in left-ventricular dysfunction.

  • Clinical Indications & Candidacy Criteria
  • Table 9.1.1: Clinical Indications and Evidence-Based Thresholds for iNO Therapy

Patient Population Indication Diagnostic Criteria / Clinical Thresholds Clinical Objectives

Term & Near-Term Neonates ( > 34 >34 > 34 weeks GA) Hypoxic respiratory failure with pulmonary hypertension FDA labeling requires clinical or echocardiographic pulmonary hypertension together with ventilatory support and other appropriate therapy; it does not specify one OI cutoff Improve oxygenation and reduce ECMO use in the indicated population

MAS, Pneumonia/Sepsis, or RDS in the labeled age group Secondary PPHN physiology Confirm pulmonary-hypertension physiology, recruit lung, treat the cause, and assess ventricular function before and during a monitored trial Improve V/Q matching and reduce right-to-left shunting in responders

Congenital Diaphragmatic Hernia (CDH) Pulmonary-hypertension physiology Response is variable; trials have not demonstrated reduced ECMO need in CDH, and left-ventricular dysfunction can worsen Specialist-selected physiologic trial with early ECMO-center coordination

Pediatric cardiac disease or surgery Pulmonary hypertensive crisis or high RV afterload Off-label, specialist-directed use based on anatomy, pressure, ventricular function, perfusion, and local protocol Reduce pulmonary pressure or RV afterload while correcting the trigger

PARDS Selected severe pulmonary-hypertension or RV-dysfunction phenotype Not routine PARDS therapy; a monitored rescue trial may be considered without delaying other escalation Possible transient oxygenation or RV benefit; no established survival benefit

The Oxygenation Index (OI)

The Oxygenation Index is an important severity and trajectory measure in invasively ventilated hypoxemic respiratory failure. It supports iNO and ECMO-center decisions but does not independently establish pulmonary hypertension, eligibility, or cannulation: Oxygenation Index (OI) = Mean Airway Pressure (Paw in cmH 2 O) × FiO 2 × 100 PaO 2 (in mmHg) \text{Oxygenation Index (OI)} = \frac{\text{Mean Airway Pressure (Paw in }\text{cmH}_2\text{O)} \times \text{FiO}_2 \times 100}{\text{PaO}_2\text{ (in mmHg)}} Oxygenation Index (OI) = PaO 2 ​ (in mmHg) Mean Airway Pressure (Paw in cmH 2 ​ O) × FiO 2 ​ × 100 ​

Lower or rising OI: Optimize lung recruitment and protective ventilation, treat the cause, assess ventricular function and pulmonary pressure, and follow the trajectory.

iNO consideration: In a term or near-term infant with hypoxic respiratory failure and evidence of pulmonary hypertension after lung recruitment, many protocols consider iNO as OI rises into the mid-teens or higher; eligibility and timing are protocol-specific.

Severe or sustained elevation: Reassess reversible problems and contact an ECMO-capable center early. An OI around or above 40 is a traditional high-risk trigger for urgent evaluation, not a stand-alone mandate for HFOV or cannulation.

Contraindication & Major Cautions

Labeled contraindication: Do not use INOmax in a neonate whose survival depends on right-to-left shunting of blood; lowering pulmonary resistance can disrupt the required systemic or pulmonary flow pattern.

Left-ventricular dysfunction or pulmonary venous obstruction: Increased pulmonary flow can raise wedge pressure and worsen pulmonary edema or heart failure. Review anatomy and ventricular function and stop therapy if this occurs.

Methemoglobin risk: Baseline red-cell disorders and concurrent oxidant drugs can alter risk. G6PD deficiency is especially relevant if methylene blue is considered for treatment; it is not itself listed as the neonatal INOmax contraindication.

  • Therapeutic Dosing & Dose-Response Mechanics Pulmonary Vasodilation & PaO2 Improvement
  • ▲
  • │ ┌─────────────────────────────────────────────── (Plateau: Maximal Vasodilation)
  • │ /
  • │ /
  • │ /
  • │ /
  • │ / ◄── Doses > 20 ppm provide NO additional vasodilation,
  • │ / and increase NO2 and methemoglobin exposure
  • │ /
  • │ /
  • │ /
  • │ /
  • │ /
  • │ /
  • │ /
  • └────┴─────────────┴──────────────────────────────┴────────────────────────►
  • 0 5 20 80 iNO (ppm)
  • Clinical Dosing Rules
  • Standard Initial Starting Dose: 20 ppm 20\text{ ppm} 20 ppm

The FDA-labeled recommended neonatal dose is 20 ppm 20\text{ ppm} 20 ppm . Trials found improved oxygenation and reduced ECMO use in the indicated population; doses above 20 ppm are not recommended because they increase toxic exposure without demonstrated additional benefit.

Doses above 20 ppm:

Routine escalation above 20 ppm has not shown added outcome benefit in neonatal PPHN and increases nitrogen-dioxide and methemoglobin exposure.

If response is inadequate, verify delivery and lung recruitment and reassess cardiac anatomy, ventricular function, disease mechanism, and rescue strategy rather than repeatedly increasing dose.

Defining a Clinical "Responder":

Define the response before starting: a prompt, reproducible improvement in oxygenation, OI, pulmonary pressure, right-ventricular function, or perfusion at unchanged or reduced support. Exact PaO2 and SpO2 thresholds vary by protocol.

If there is no meaningful response after delivery and lung inflation are verified, reassess anatomy, ventricular function, lung disease, and rescue strategy. Routine escalation above 20 ppm has not shown added outcome benefit in neonatal PPHN and increases toxic exposure; any exception requires specialist direction and close NO2 and methemoglobin monitoring.